HOOKIPA Pharma to Participate in Upcoming SVB Leerink Global Healthcare Conference
Rhea-AI Summary
HOOKIPA Pharma Inc. (NASDAQ: HOOK) will participate in the virtual SVB Leerink Global Healthcare Conference on February 25, 2021, with a fireside discussion scheduled for 9:20 AM ET. This event will be accessible via a live audio webcast on HOOKIPA's website, alongside an archived replay available for 30 days post-event. HOOKIPA is advancing a new class of immunotherapeutics through its proprietary arenavirus platform, focusing on treatments for cancers and infectious diseases, including a Phase 1/2 trial for HPV-positive cancers and a Phase 2 trial for a cytomegalovirus vaccine.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, HOOK gained 7.63%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
NEW YORK and VIENNA, Austria, Feb. 16, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will participate in the upcoming virtual SVB Leerink Global Healthcare Conference:
- Fireside Discussion: Thursday, February 25, 2021 at 9:20 AM ET
The live audio webcast of the presentation will be available within the Investors & Media section of HOOKIPA’s website at https://ir.hookipapharma.com/events. An archived replay will be accessible for 30 days following the event.
About HOOKIPA
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body’s immune system. HOOKIPA’s proprietary arenavirus-based technologies, non-replicating and replicating, are designed induce robust antigen-specific CD8+ T cells and pathogen-neutralizing antibodies. HOOKIPA’s viral vectors target antigen presenting cells in vivo to activate the immune system. Both technologies enable repeat administration to augment and refresh immune responses. As a monotherapy, HOOKIPA’s replicating arenavirus technology has the potential to induce CD8+ T cell response levels previously not achieved by other immuno-therapy approaches.
HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens, and next-generation antigens. The lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papilloma Virus 16-positive cancers in a Phase 1/2 clinical trial.
HOOKIPA’s non-replicating prophylactic cytomegalovirus (CMV) vaccine candidate is currently in a Phase 2 clinical trial for patients awaiting kidney transplantation. To expand its infectious disease portfolio, HOOKIPA entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to research arenavirus-based functional cures for HIV and chronic Hepatitis B infections.
Find out more about HOOKIPA online at www.hookipapharma.com.
| For further information, please contact: | ||
| Media | Investors | |
| Nina Waibel | Matt Beck | |
| Senior Director - Communications | Executive Director - Investor Relations | |
| nina.waibel@hookipapharma.com | matthew.beck@hookipapharma.com | |
FAQ
What is HOOKIPA Pharma's participation in the SVB Leerink Global Healthcare Conference?
Where can I watch HOOKIPA's presentation at the SVB Leerink Conference?
What are HOOKIPA Pharma's lead product candidates?
What trials is HOOKIPA currently conducting?
Is HOOKIPA collaborating on any infectious disease research?
